ClinConnect ClinConnect Logo
Search / Trial NCT04482439

Evaluation of Vision After Vivity IOL Implantation With a Target of Slight Myopia in the Non-dominant Eye

Launched by NEWSOM EYE & LASER CENTER · Jul 17, 2020

Trial Information

Current as of May 20, 2025

Completed

Keywords

ClinConnect Summary

This study is a single-arm unmasked clinical evaluation study of binocular distance-corrected near (40 cm) visual acuity, when the non-dominant eye is targeted for slight myopia, after successful bilateral cataract surgery. Subjects will be assessed pre-operatively, operatively and at 1 day, 1 month and 3 months post-operatively. Clinical evaluations will include administration of a visual disturbance questionnaire (QUVID), patient-reported spectacle independence questionnaire (PRSIQ), and a satisfaction questionnaire (IOLSAT), as well as measurement of bilateral visual acuity and manifest ...

Gender

ALL

Eligibility criteria

  • Inclusion Criteria:
  • • Presenting for uncomplicated bilateral cataract surgery and have an interest in spectacle independence using an EDF IOL
  • Meet the requirements for on-label implantation of the EDF IOL
  • Gender: Males and Females.
  • Age: 40 or older.
  • Willing and able to provide written informed consent for participation in the study.
  • Willing and able to comply with scheduled visits and other study procedures.
  • Have good ocular health, with no pathology that compromises visual acuity (outside of residual refractive error and cataract)
  • Have regular corneal astigmatism with a magnitude that can be treated with a non-toric IOL or toric IOL.
  • Have 20/32 (0.2 logMAR) or better potential acuity in both eyes
  • Exclusion Criteria:
  • • Irregular astigmatism (e.g. keratoconus)
  • Corneal pathology (e.g. scar, dystrophy, pterygium, severe dry eye)
  • Monocular status (e.g. amblyopia)
  • Previous radial keratotomy, corneal refractive surgery or other corneal surgery (e.g. corneal transplant, DSAEK, lamellar keratoplasty)
  • Previous anterior or posterior chamber surgery (e.g., vitrectomy, laser iridotomy)
  • Diabetic retinopathy
  • Macular pathology (e.g. ARMD, ERM)
  • History of retinal detachment
  • Subjects who have an unstable acute or chronic disease or illness that would confound the results of this investigation (e.g., immunocompromised, connective tissue disease, clinically significant atopic disease, diabetes, and any other such disease or illness), that are known to affect postoperative visual acuity.
  • Participation in any investigational drug or device trial within the previous 30 days prior to the start date of this trial (or currently participating).

About Newsom Eye & Laser Center

Newsom Eye & Laser Center is a leading ophthalmic research and clinical trial sponsor dedicated to advancing innovative treatments in eye care. With a commitment to enhancing patient outcomes, the Center specializes in cutting-edge procedures and technologies for a range of ocular conditions. Led by a team of experienced professionals, Newsom Eye & Laser Center prioritizes patient safety and rigorous scientific methodology, ensuring that all clinical trials adhere to the highest ethical and regulatory standards. Through collaboration with top researchers and healthcare providers, the Center aims to contribute significantly to the field of ophthalmology and improve the quality of life for individuals affected by vision-related disorders.

Locations

Sebring, Florida, United States

Patients applied

0 patients applied

Trial Officials

Thomas Newsom, MD

Principal Investigator

Newsom Eye & Laser Center

Timeline

First submit

Trial launched

Trial updated

Estimated completion

Not reported

Similar Trials